Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models

J Neurooncol. 2007 Mar;82(1):41-7. doi: 10.1007/s11060-006-9247-5. Epub 2006 Sep 20.

Abstract

Convection-enhanced delivery (CED) is a local infusion technique, which delivers chemotherapeutic agents directly to the central nervous system, circumventing the blood-brain barrier and reducing systemic side effects. CED distribution is significantly increased if the infusate is hydrophilic. This study evaluated the safety and efficacy of CED of nimustine hydrochloride: 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU), a hydrophilic nitrosourea, in rat 9 L: brain tumor models. The local neurotoxicity of ACNU delivered via CED was examined in normal rat brains, and the maximum tolerated dose (MTD) was estimated at 0.02 mg/rat. CED of ACNU at the MTD produced significantly longer survival time than systemic administration (P < 0.05, log-rank test). Long-term survival (80 days) and eradication of the tumor occurred only in the CED-treated rats. The tissue concentration of ACNU was measured by high-performance liquid chromatography, which revealed that CED of ACNU at the dose of 100-fold less total drug than intravenous injection carried almost equivalent concentrations of ACNU into rat brain tissue. CED of hydrophilic ACNU is a promising strategy for treating brain tumors.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Brain / drug effects
  • Brain / metabolism
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Cell Line, Tumor
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Convection*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems / methods
  • Gliosarcoma / drug therapy*
  • Gliosarcoma / mortality
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Nimustine / administration & dosage*
  • Nimustine / pharmacokinetics
  • Random Allocation
  • Rats
  • Rats, Inbred F344
  • Rats, Sprague-Dawley
  • Survival Analysis
  • Tissue Distribution
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Nimustine